IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.561
AS - Asia 3.668
EU - Europa 3.136
SA - Sud America 647
AF - Africa 127
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.437
SG - Singapore 1.497
RU - Federazione Russa 796
VN - Vietnam 711
HK - Hong Kong 562
BR - Brasile 479
IT - Italia 432
IE - Irlanda 425
CN - Cina 394
DE - Germania 274
FR - Francia 267
SE - Svezia 262
UA - Ucraina 220
GB - Regno Unito 144
IN - India 134
FI - Finlandia 90
BD - Bangladesh 64
AR - Argentina 61
MX - Messico 54
CA - Canada 45
NL - Olanda 45
IQ - Iraq 41
PL - Polonia 40
ES - Italia 39
JP - Giappone 36
ZA - Sudafrica 34
CI - Costa d'Avorio 30
TR - Turchia 29
AT - Austria 25
VE - Venezuela 24
PK - Pakistan 23
CO - Colombia 22
BE - Belgio 21
UZ - Uzbekistan 21
MA - Marocco 20
EC - Ecuador 19
PH - Filippine 19
SA - Arabia Saudita 19
PY - Paraguay 15
TH - Thailandia 13
ID - Indonesia 11
LT - Lituania 11
AE - Emirati Arabi Uniti 10
DZ - Algeria 10
JO - Giordania 9
AU - Australia 8
CL - Cile 8
KR - Corea 8
TN - Tunisia 8
TW - Taiwan 8
AZ - Azerbaigian 7
EG - Egitto 7
IL - Israele 7
BO - Bolivia 6
KE - Kenya 6
LB - Libano 6
JM - Giamaica 5
OM - Oman 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
HN - Honduras 4
KZ - Kazakistan 4
MY - Malesia 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
RS - Serbia 4
AM - Armenia 3
BG - Bulgaria 3
CH - Svizzera 3
GR - Grecia 3
HU - Ungheria 3
PA - Panama 3
RO - Romania 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
LY - Libia 2
MD - Moldavia 2
MN - Mongolia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CU - Cuba 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
Totale 18.133
Salva come PNG Salva come JPEG
Città #
Des Moines 1.774
Ashburn 1.256
Singapore 1.112
Chandler 1.018
Hong Kong 550
Fairfield 535
San Jose 499
Dallas 474
Jacksonville 456
Dublin 423
Houston 335
Boardman 278
Wilmington 248
Woodbridge 248
Ho Chi Minh City 234
Seattle 220
Cambridge 216
The Dalles 179
Hanoi 173
Lawrence 163
Princeton 163
Lauterbourg 157
San Mateo 142
Ann Arbor 123
Los Angeles 116
New York 112
Moscow 111
Beijing 98
Redmond 87
San Diego 65
Helsinki 62
Washington 60
Munich 52
Pune 51
Council Bluffs 47
Santa Clara 47
Orem 45
Chicago 44
São Paulo 44
Milan 39
Da Nang 38
Hefei 34
London 34
Abidjan 30
Tokyo 30
Frankfurt am Main 29
Warsaw 29
Nuremberg 28
Turku 26
Chennai 25
Columbus 25
Stockholm 25
Montreal 22
San Francisco 22
Haiphong 21
Ancona 20
Centro 20
Manchester 20
Mexico City 20
Rome 20
Amsterdam 19
Salt Lake City 19
Tashkent 19
Phoenix 18
Baghdad 16
Brussels 16
Buffalo 15
Guangzhou 15
Brooklyn 14
Atlanta 13
Boston 13
Denver 13
Falls Church 13
Kilburn 13
Mumbai 13
Norwalk 13
Cedar Knolls 12
Johannesburg 12
Shanghai 12
Hải Dương 11
Riyadh 11
Brasília 10
Miami 10
Shenzhen 10
St Petersburg 10
Can Tho 9
Charlotte 9
New Delhi 9
Querétaro 9
Tampa 9
Amman 8
Ankara 8
Belo Horizonte 8
Campinas 8
Dhaka 8
Elk Grove Village 8
Porto Alegre 8
Rio de Janeiro 8
Wuhan 8
Biên Hòa 7
Totale 13.038
Salva come PNG Salva come JPEG
Nome #
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 272
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 252
Idiopathic anaphylaxis 251
Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome 246
Anaphylaxis 186
Diagnosing, managing and preventing anaphylaxis: Systematic review 180
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 170
ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics 156
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 156
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 155
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 151
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 151
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 149
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 148
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 146
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 143
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 139
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 139
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 138
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 137
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 136
In vivo diagnosis of allergic diseases - allergen provocation tests 135
Advances in Hymenoptera venom immunotherapy 133
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 132
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 131
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 131
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 130
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 130
EAACI Molecular Allergology User's Guide 129
The role of component-resolved diagnosis in Hymenoptera venom allergy 129
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 128
Epidemiology of hymenoptera allergy 128
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 127
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 127
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 126
Contraindications to immunotherapy: A global approach 125
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 125
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 125
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 124
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 124
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 123
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 123
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 122
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 122
Risk Factors and Characteristics of Biphasic Anaphylaxis 122
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 121
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 121
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 120
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 120
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 120
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper 117
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies 117
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 117
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 117
Diagnosis of Hymenoptera venom allergy 115
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 114
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 113
Common Variable Immunodeficiency in Elderly Patients: A Long-Term Clinical Experience 112
Hymenoptera Venom Allergy: Management of children and adults in clinical practice 111
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 111
EAACI anaphylaxis guidelines: Systematic review protocol 111
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper 111
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 110
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 110
COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy 110
Allergy to stings and bites from rare or locally important arthropods: Worldwide distribution, available diagnostics and treatment 109
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 109
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 108
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 107
World Allergy Organization anaphylaxis guidelines: Summary 107
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 107
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients 107
Intraoperative anaphylaxis: verba volant, scripta manent! 107
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 106
International consensus on (ICON) anaphylaxis 106
EAACI guidelines: Anaphylaxis (2021 update) 106
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 105
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 105
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 105
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 104
Lysozyme, a new allergen in donkey's milk 102
High long-term efficacy of venom immunotherapy after discontinuation 102
Adherence to the rhinitis management plan of allergic rhinitis 102
Congruence between international guidelines and mite specific immunotherapy prescribing practices 102
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 101
The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? 101
A case of fatal biphasic anaphylaxis secondary to multiple stings: adrenalin and/or a longer observation time could have saved the patient? 100
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 100
The natural history and epidemiology of insect venom allergy: clinical implications 100
Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper 99
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 99
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 99
Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine? 99
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 98
Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? 98
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry 97
Hymenoptera Venom Allergy - European Academy of Allergy and Clinical Immunology Monographs 96
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 96
Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy 96
Mast cell diseases and the severity and course of intraoperative anaphylaxis 95
Totale 12.530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.852
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.852
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021457 0 0 0 0 0 0 0 0 0 143 221 93
2021/20221.200 61 235 18 35 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.392 268 39 119 139 223 271 23 46 7 53 19 185
2024/20252.735 100 232 100 74 63 174 207 94 809 210 257 415
2025/20266.317 342 397 414 512 711 545 1.416 768 674 538 0 0
Totale 18.455